Daily Respiratory Research Analysis
Three high-impact respiratory studies stand out: a Nature Microbiology report demonstrates a respiratory-delivered, antibiotic-inactivated Bordetella pertussis vaccine that induces IL-17+ tissue-resident T cells and sterilizing nasal immunity; a PNAS modeling analysis estimates U.S. 2022–2023 influenza vaccination averted ~70,000 hospitalizations, with major indirect protection via young adults; and a JCI Insight study reveals low baseline interferon tone in pediatric asthma epithelium as a caus
Summary
Three high-impact respiratory studies stand out: a Nature Microbiology report demonstrates a respiratory-delivered, antibiotic-inactivated Bordetella pertussis vaccine that induces IL-17+ tissue-resident T cells and sterilizing nasal immunity; a PNAS modeling analysis estimates U.S. 2022–2023 influenza vaccination averted ~70,000 hospitalizations, with major indirect protection via young adults; and a JCI Insight study reveals low baseline interferon tone in pediatric asthma epithelium as a causal driver of severe rhinovirus responses, reversible by prophylactic IFN-β.
Research Themes
- Mucosal vaccination and tissue-resident immunity for respiratory pathogens
- Indirect protection and age-targeting strategies in influenza vaccination policy
- Epithelial interferon tone as a modifiable determinant in pediatric asthma exacerbations
Selected Articles
1. Respiratory immunization using antibiotic-inactivated Bordetella pertussis confers T cell-mediated protection against nasal infection in mice.
Aerosol or intranasal immunization with ciprofloxacin-inactivated B. pertussis induced IL-17–producing CD4 tissue-resident memory T cells that recruited neutrophils and conferred robust protection against both lung and nasal infection. Protection was abrogated by CD4 depletion or IL-17 neutralization, and unlike parenteral whole-cell vaccines, the aerosol AIBP did not induce systemic pro-inflammatory cytokines.
Impact: This study presents a novel, mechanistically validated mucosal vaccination platform that achieves sterilizing nasal immunity against B. pertussis—an unmet need with current acellular vaccines. It advances the paradigm of tissue-resident T cell–based protection for respiratory pathogens.
Clinical Implications: Supports development of respiratory-delivered inactivated-pathogen vaccines to induce mucosal IL-17–TRM responses for sterilizing immunity, potentially reducing transmission. Provides a safety signal with minimal systemic inflammation compared with parenteral whole-cell vaccines.
Key Findings
- Ciprofloxacin-inactivated B. pertussis delivered by aerosol/intranasal routes protected against lung and nasal infection.
- Vaccine induced IL-17–producing CD4 tissue-resident memory T cells and neutrophil recruitment in the respiratory tract.
- Protection required CD4 T cells and IL-17; depletion or neutralization abrogated efficacy.
- Aerosol AIBP did not trigger systemic pro-inflammatory cytokines seen with parenteral whole-cell vaccines.
Methodological Strengths
- Mechanistic validation with CD4 depletion and IL-17 neutralization demonstrating causal pathways.
- Use of respiratory (aerosol/intranasal) immunization and assessment of sterilizing nasal immunity.
- Comparative safety profiling versus parenteral whole-cell vaccine (cytokine readouts).
Limitations
- Preclinical murine model; human immunogenicity and durability are unknown.
- Manufacturing and regulatory pathways for antibiotic-inactivated whole-pathogen mucosal vaccines remain to be defined.
Future Directions: Conduct translational immunogenicity and challenge studies in larger animals and early human trials; define correlates of mucosal protection; compare against acellular and live-attenuated platforms; assess impact on transmission.
The Gram-negative bacterium Bordetella pertussis causes whooping cough (pertussis), a severe respiratory disease, especially in young children, which is resurgent despite high vaccine coverage. The current acellular pertussis vaccine prevents severe disease but does not prevent nasal infection with B. pertussis. This parenterally delivered vaccine induces potent circulating antibody responses but limited respiratory tissue-resident memory T cells and IgA responses. Here we developed a vaccine appro
2. Estimated impact of 2022-2023 influenza vaccines on annual hospital burden in the United States.
Using a transmission model with vaccine-derived protection against infection and hospitalization, influenza vaccination in 2022–2023 was estimated to prevent ~69,886 hospitalizations nationwide, with 57% attributable to indirect effects on susceptibility and transmission. State-level analyses showed a strong negative correlation between young adult vaccination rates and hospital burden; nearly half of averted hospitalizations in ≥65-year-olds were due to vaccinating younger groups.
Impact: Quantifies indirect protection from vaccinating younger adults, informing age-targeted strategies to reduce hospitalization burden. Provides timely policy-relevant evidence for optimizing influenza vaccination programs.
Clinical Implications: Supports increasing vaccination coverage among young adults to protect high-risk groups through indirect effects; highlights need for better estimates of vaccine effectiveness against infection to inform transmission models.
Key Findings
- Estimated 69,886 (95% CI: 51,860–84,575) influenza-related hospitalizations were averted in 2022–2023.
- Approximately 57% of averted hospitalizations were due to reduced susceptibility and onward transmission (indirect protection).
- Young adult (18–49 y) vaccination rates negatively correlated with state-level hospital burden.
- Nearly half of averted hospitalizations among ≥65 y resulted from vaccinating younger age groups.
Methodological Strengths
- Transmission model integrating protection against infection and severe disease, capturing indirect effects.
- State-level correlation analysis supporting model inferences; uncertainty quantified with CIs.
Limitations
- Vaccine effectiveness against infection is uncertain, and model results depend on assumptions.
- Observational correlation cannot prove causality; unmeasured confounders may remain.
Future Directions: Improve direct estimates of VE against infection; evaluate targeted vaccination campaigns in young adults; integrate real-time mobility and contact data to refine indirect effect estimates.
During the COVID-19 pandemic early years, infection prevention measures suppressed transmission of seasonal influenza and other respiratory viruses. The early onset and moderate severity of the US 2022-2023 influenza season may have resulted from reduced use of nonpharmaceutical interventions or lower population immunity after 2 y of limited influenza virus circulation. We used a mathematical model of influenza virus transmission that incorporates vaccine-derived protection against both infection
3. Bronchial Epithelial Transcriptome Reveals Dysregulated Interferon and InflammatoryResponses to Rhinovirus in Exacerbation-Prone Pediatric Asthma.
Exacerbation-prone pediatric asthma epithelium had higher rhinovirus replication and exaggerated interferon, inflammatory, stress, and remodeling responses, linked to low pre-infection interferon-stimulated gene (ISG) tone (e.g., CXCL10). Single-cell RNA-seq localized responses to secretory immune-response, tuft, and basal cells. Prophylactic IFN-β reduced viral replication and normalized downstream responses, implicating low baseline IFN tone as a modifiable causal determinant.
Impact: Identifies low epithelial interferon tone as a causal, modifiable driver of severe rhinovirus responses in pediatric asthma and demonstrates proof-of-concept mitigation with IFN-β. Provides cell-type–resolved mechanisms that may inform biomarker-driven interventions.
Clinical Implications: Suggests stratifying exacerbation-prone children by epithelial ISG biomarkers and exploring prophylactic or early IFN-β therapy to blunt viral replication and downstream inflammatory remodeling.
Key Findings
- Exacerbation-prone pediatric asthma epithelium exhibited greater rhinovirus replication and exaggerated IFN/inflammatory/stress/remodeling responses.
- Low pre-infection ISG expression and low CXCL10 protein levels associated with adverse responses.
- Single-cell RNA-seq identified secretory immune-response, tuft, and basal cells as key contributors.
- Prophylactic IFN-β reduced viral replication and normalized downstream host responses.
Methodological Strengths
- Integrated bulk and single-cell transcriptomics with organotypic human pediatric bronchial epithelium.
- Functional intervention (IFN-β) demonstrating causality and reversibility.
- Protein validation of ISG (e.g., CXCL10) supporting transcriptomic findings.
Limitations
- Ex vivo model without clinical outcomes; sample size details not specified in abstract.
- Generalizability across asthma phenotypes and viral strains remains to be established.
Future Directions: Pilot trials of IFN-β in biomarker-selected children; longitudinal studies to define ISG-based risk stratification; delineate optimal timing/dose and safety for prophylaxis.
Host factors influencing susceptibility to rhinovirus-induced asthma exacerbations remain poorly characterized. Using organotypic bronchial epithelial cultures from well-characterized children with asthma and healthy children, this study investigated viral load kinetics and resultant host responses by bulk and single-cell transcriptomics and targeted protein analyses. Bronchial epithelium from exacerbation-prone children exhibited greater rhinovirus replication and a cascade of exaggerated downst